Volume 34, Issue 4 (7-2023)
Studies in Medical Sciences 2023, 34(4): 182-190 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Tanomand A, Abbasi M. PREPARATION AND EVALUATION OF PROPERTIES OF PSEUDOMONAS AERUGINOSA EXOTOXIN A CONJUGATE WITH GOLD NANOPARTICLES. Studies in Medical Sciences 2023; 34 (4) :182-190
URL: http://umj.umsu.ac.ir/article-1-5884-en.html
URL: http://umj.umsu.ac.ir/article-1-5884-en.html
Assistant Professor, Department of Microbiology, Malekan Branch, Islamic Azad University, Malekan, Iran (Corresponding Author) , masomeabasi55@yahoo.com
Abstract: (1922 Views)
Background & Aims: Pseudomonas aeruginosa is an opportunistic pathogen and most important cause of hospital infections, which causes septicemia and death through various virulence factors such as exotoxin A. In the present study, P. aeruginosa exotoxin A (as a toxic factor) was prepared with the aim of obtaining a new recombinant vaccine candidate and conjugated with gold nanoparticles and its immunogenic effects were evaluated in an animal model.
Materials & Methods: Native exotoxin A was first extracted and purified from culture medium of P. aeruginosa by selective sedimentation and dialysis. In order to produce recombinant exotoxin A, genomic DNA of this bacterium was cloned in Escherichia coli using a suitable vector. Gold nanoparticles were prepared using Turkevich method and conjugated to the prepared exotoxin A by electrostatic force. Finally, the size and conjugation were confirmed using electron microscopy and fourier-transform infrared (FTIR) spectroscopy, respectively. Finally, quantitative data were presented in average of three repetitions and standard deviation, as well as qualitative data were presented in frequency (percentage).
Results: The obtained results showed that P. aeruginosa exotoxin A can be extracted from the culture medium with relative purity. Also, expression of recombinant protein by E. coli and using of E. coli PET22b vector led to production of recombinant exotoxin A in high concentration. The gold nanoparticles were conjugated with both intrinsic and recombinant exotoxin A. The obtained results showed that the gold nanoparticle is well conjugated with exotoxin A.
Conclusion: In general, the present study showed that it is possible to produce recombinant and natural exotoxin A with high concentrations in the laboratory and conjugate it with gold nanoparticles.
Materials & Methods: Native exotoxin A was first extracted and purified from culture medium of P. aeruginosa by selective sedimentation and dialysis. In order to produce recombinant exotoxin A, genomic DNA of this bacterium was cloned in Escherichia coli using a suitable vector. Gold nanoparticles were prepared using Turkevich method and conjugated to the prepared exotoxin A by electrostatic force. Finally, the size and conjugation were confirmed using electron microscopy and fourier-transform infrared (FTIR) spectroscopy, respectively. Finally, quantitative data were presented in average of three repetitions and standard deviation, as well as qualitative data were presented in frequency (percentage).
Results: The obtained results showed that P. aeruginosa exotoxin A can be extracted from the culture medium with relative purity. Also, expression of recombinant protein by E. coli and using of E. coli PET22b vector led to production of recombinant exotoxin A in high concentration. The gold nanoparticles were conjugated with both intrinsic and recombinant exotoxin A. The obtained results showed that the gold nanoparticle is well conjugated with exotoxin A.
Conclusion: In general, the present study showed that it is possible to produce recombinant and natural exotoxin A with high concentrations in the laboratory and conjugate it with gold nanoparticles.
Type of Study: Research |
Subject:
میکروبیولوژی
References
1. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin Microbiol Infect 2007;13(6):560-78. [DOI:10.1111/j.1469-0691.2007.01681.x] [PMID]
2. Oruji F, Baghbani Arani F, Mahdavi Ortakand M. Evaluation of the gene expression of IL-1β and Casp-1 related to inflammation process in glomerulonephritis patients. J Anim Environ 2018;10(3):477-82. [Google Scholar]
3. Mahdavi S, Hajazimian S, Isazadeh A, Babash Pour M, Shishehgar R. Study of the antioxidant and antimicrobial effects of the ethanolic extract of Eucalyptus camaldulensis Dehnh against infectious bacteria isolated from clinical and animal sources. J Compar Pathobiol 2017;13(4):2063-70. [Google Scholar]
4. Holder IA. Pseudomonas immunotherapy: a historical overview. Vaccine 2004;22(7):831-9. [DOI:10.1016/j.vaccine.2003.11.028] [PMID]
5. Hassett DJ, Korfhagen TR, Irvin RT, Schurr MJ, Sauer K, Lau GW, et al. Pseudomonas aeruginosa biofilm infections in cystic fibrosis: insights into pathogenic processes and treatment strategies. Expert Opin Ther Targets 2010;14(2):117-30. [DOI:10.1517/14728220903454988] [PMID]
6. Jadid MF, Shademan B, Chavoshi R, Seyyedsani N, Aghaei E, Taheri E, et al. Enhanced anticancer potency of hydroxytyrosol and curcumin by PLGA‐PAA nano‐encapsulation on PANC‐1 pancreatic cancer cell line. Environ Toxicol 2021;36(6):1043-51. [DOI:10.1002/tox.23103] [PMID]
7. Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int J Pharm 2005;299(1-2):155-66. [DOI:10.1016/j.ijpharm.2005.04.037] [PMID]
8. Tanomand A, Najar Peerayeh S, Farajnia S, Majidi J. Protective properties of nontoxic recombinant exotoxin A (domain I-II) against Pseudomonas aeruginosa infection. Iran J Biotechnol 2013;11(3):193-8. [DOI:10.5812/ijb.10149]
9. Farajnia S, Peerayeh SN, Tanomand A, Majidi J, Goudarzi G, Naghili B, et al. Protective efficacy of recombinant exotoxin A-flagellin fusion protein against Pseudomonas aeruginosa infection. Can J Microbiol 2015;61(1):60-4. [DOI:10.1139/cjm-2014-0501] [PMID]
10. Michalska M, Wolf P. Pseudomonas Exotoxin A: optimized by evolution for effective killing. Front Microbiol 2015;6:963. [DOI:10.3389/fmicb.2015.00963] [PMID] [PMCID]
11. Abbasi M, Kafilzadeh F, Tanomand A, Zolghadri S, Hosainzadegan H. Gold Nanoparticles Conjugating Recombinant Nontoxic Pseudomonas Exotoxin A as a Vaccine Candidate for Pseudomonas aeruginosa Infections. Mol Genet Microbiol Virol 2021;36(Suppl 1):7-12. [DOI:10.3103/S0891416821050025]
12. Azam MW, Khan AU. Updates on the pathogenicity status of Pseudomonas aeruginosa. Drug Discov Today 2019;24(1):350-9. [DOI:10.1016/j.drudis.2018.07.003] [PMID]
13. Safari Zanjani L, Shapouri R, Dezfulian M, Mahdavi M, Shafiee Ardestani M. Exotoxin A-PLGA nanoconjugate vaccine against Pseudomonas aeruginosa infection: Protectivity in murine model. World J Microbiol Biotechnol 2019;35(6):1-9. [DOI:10.1007/s11274-019-2669-y] [PMID]
14. Shadman Z, Farajnia S, Pazhang M, Tohidkia M, Rahbarnia L, Najavand S, et al. Isolation and characterizations of a novel recombinant scFv antibody against exotoxin A of Pseudomonas aeruginosa. BMC Infect Dis 2021;21(1):1-9. (Persian) [DOI:10.1186/s12879-021-05969-0] [PMID] [PMCID]
15. Gholami N, Cohan RA, Razavi A, Bigdeli R, Dashbolaghi A, Asgary V. Cytotoxic and apoptotic properties of a novel nano‐toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A. J Cell Physiol 2020;235(4):3711-20. (Persian) [DOI:10.1002/jcp.29265] [PMID]
16. Kaplan G, Mazor R, Lee F, Jang Y, Leshem Y, Pastan I. Improving the In Vivo Efficacy of an Anti-Tac (CD25) Immunotoxin by Pseudomonas Exotoxin A Domain II EngineeringHighly Active Engineered Anti-Tac (CD25) Immunotoxins. Mol Cancer Ther 2018;17(7):1486-93. [DOI:10.1158/1535-7163.MCT-17-1041] [PMID] [PMCID]
17. Eftekharivash L, Farajnia S, Najar Peerayeh S, Tanomand A. Optimization of expression and in vitro characteristics evaluation of Pseudomonas aeruginosa recombinant exotoxin A (domains I and II). J North Khorasan Uni Med Sci 2016;7(3):495-507. [DOI:10.29252/jnkums.7.3.495]
18. Zawrah MF, El-Moez SA, Center D. Antimicrobial activities of gold nanoparticles against major foodborne pathogens. Life Sci J 2011;8(4):37-44. [Google Scholar]
19. Nazari ZE, Banoee M, Sepahi AA, Rafii F, Shahverdi AR. The combination effects of trivalent gold ions and gold nanoparticles with different antibiotics against resistant Pseudomonas aeruginosa. Gold Bull 2012;45(2):53-9. (Persian) [DOI:10.1007/s13404-012-0048-7]
20. Cryz Jr SJ, Fiirer E, Sadoff JC, Germanier R, Pastan I, Willingham MC, et al. Use of Pseudomonas aeruginosa toxin A in the construction of conjugate vaccines and immunotoxins. Rev Infect Dis 1987;9(Supplement 5):644-9. [DOI:10.1093/clinids/9.Supplement_5.S644] [PMID]
21. Li C, Li D, Wan G, Xu J, Hou W. Facile synthesis of concentrated gold nanoparticles with low size-distribution in water: temperature and pH controls. Nanoscale Res Lett 2011;6(1):440.
https://doi.org/10.1186/1556-276X-9-440 [DOI:10.1186/1556-276X-6-440]
22. Shah M, Badwaik V, Kherde Y, Waghwani HK, Modi T, Aguilar ZP, et al. Gold nanoparticles: various methods of synthesis and antibacterial applications. Front Biosci 2014;19(8):1320-44. [DOI:10.2741/4284] [PMID]
23. Rana S, Bajaj A, Mout R, Rotello VM. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 2012;64(2):200-16. [DOI:10.1016/j.addr.2011.08.006] [PMID] [PMCID]
24. Massich MD, Giljohann DA, Schmucker AL, Patel PC, Mirkin CA. Cellular Response of Polyvalent Oligonucleotide− Gold Nanoparticle Conjugates. ACS Nano 2010;4(10):5641-6. [DOI:10.1021/nn102228s] [PMID] [PMCID]
25. Cai W, Gao T, Hong H, Sun J. Applications of gold nanoparticles in cancer nanotechnology. Nanotechnol Sci Appl 2008;1:17-32. [DOI:10.2147/NSA.S3788] [PMID] [PMCID]
26. Chen YS, Hung YC, Liau I, Huang GS. Assessment of the in vivo toxicity of gold nanoparticles. Nanoscale Res Lett 2009;4(8):858-64. [DOI:10.1007/s11671-009-9334-6] [PMID] [PMCID]
27. Connor EE, Mwamuka J, Gole A, Murphy CJ, Wyatt MD. Gold nanoparticles are taken up by human cells but do not cause acute cytotoxicity. [Google Scholar]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
